ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Publications / Posters

Technology

  • Home
  • Technology
  • Publications / Posters
Technology

Technology

  • Overview
  • Lysins
  • Amurins
  • Publications / Posters
  • Video Library
  • « Previous
  • 1
  • 2
  • 3
Inflammatory Markers in a Phase 1 Placebo Controlled Dose Escalating Study of Intravenous Doses of CF-301 in Human Subjects

Inflammatory Markers in a Phase 1 Placebo Controlled Dose Escalating Study of Intravenous Doses of CF-301 in Human Subjects

Presented at ASM Microbe 2017, June 2, 2017
Low Propensity of Resistance Development In Vitro in Staphylococcus aureus with Lysin CF-301

Low Propensity of Resistance Development In Vitro in Staphylococcus aureus with Lysin CF-301

Presented at ASM Microbe 2017, June 2, 2017
The Sub-MIC Effect of CF-301 on Staphylococcus aureus

The Sub-MIC Effect of CF-301 on Staphylococcus aureus

Presented at ASM Microbe 2017, June 2, 2017
Quality Control Studies of CF-301 versus Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212

Quality Control Studies of CF-301 versus Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212

Presented at ASM Microbe 2017, June 2, 2017
Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301

Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301

Presented at 27th ECCMID, April 22, 2017
Long Term Immunology Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of CF-301 in Human Volunteers

Long Term Immunology Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of CF-301 in Human Volunteers

Presented at 27th ECCMID, April 22, 2017
Staphylococcus aureus Resistance to Lysin CF-301 Does Not Arise in Human Serum

Staphylococcus aureus Resistance to Lysin CF-301 Does Not Arise in Human Serum

Oral Presentation at ASM Microbe 2016, June 20
Post-Antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus in Human Serum

Post-Antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus in Human Serum

Oral Presentation at ASM Microbe 2016, June 20
PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose

PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose

Presented at ASM Microbe 2016, June 18
Results of the First In Human Study of Lysin CF-301 Evaluating the Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers

Results of the First In Human Study of Lysin CF-301 Evaluating the Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers

Presented at 26th ECCMID, April 9, 2016
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter